Advertisement

NEW YORK, July 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Acute Coronary Syndrome (ACS) Drug Market 

http://www.reportlinker.com/p0567592/Acute-Coronary-Syndrome-ACS-Drug-Market .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market.

Our report gives you revenue forecasts to 2021 for treating acute coronary syndrome (ACS). You will find market predictions at total world, submarket, product and national levels. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our study covers ACS treatments, including those for unstable angina (UA) and acute myocardial infarction (AMI). You will see commercial prospects for platelet aggregation inhibitors, anticoagulant treatments, fibrinolytic agents and their subgroups to 2021. 

You will see how drugs like Plavix, Effient/Efient, ReoPro, Integrilin, Aspirin Cardio, Lovenox, Angiomax/Angiox, Arixtra and Metalyse/TNKase will perform to 2021. Our report provides many revenue forecasts and discussions, giving answers you need. 

In particular, we discuss the R&D pipeline. There are opportunities for original and generic drugs for treating acute coronary syndrome from 2011 onwards. 

We help you to assess the ACS treatment industry and market's strengths, weaknesses, trends and revenue opportu

'/>"/>

SOURCE

Advertisement
Advertisement